ClinicalTrials.gov
ClinicalTrials.gov Menu

Brief Intervention for Justice-Involved Substance Users

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03308877
Recruitment Status : Not yet recruiting
First Posted : October 13, 2017
Last Update Posted : October 13, 2017
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
MarcSwogger, University of Rochester

Brief Summary:
This is a randomized clinical trial to study ways of helping justice-involved people change to more healthy behavior.

Condition or disease Intervention/treatment Phase
Substance Use Violence Behavioral: BMI Behavioral: Stadard Care (SC) Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Brief Intervention for Justice-Involved Substance Users: Moderators and Mechanisms of Change
Estimated Study Start Date : December 1, 2018
Estimated Primary Completion Date : July 1, 2022
Estimated Study Completion Date : July 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Abuse
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Brief Motivational Intervention (BMI) Behavioral: BMI
Four 45-minute, brief motivational sessions for substance use
Behavioral: Stadard Care (SC)
Standard procedures at pretrial program + assessement
Active Comparator: Standard Care (SC) Behavioral: Stadard Care (SC)
Standard procedures at pretrial program + assessement



Primary Outcome Measures :
  1. Percent Days Abstinent [ Time Frame: 6 months ]
    Percent Days not using alcohol or drugs

  2. Substance Use Consequences [ Time Frame: 6 months ]
    Short Inventory of Problems with Alcohol or Drugs (SIP-AD) will be used to determine extent of drug use consequences. 15 items (0-15) - higher = more problems

  3. Violent Charges [ Time Frame: 2 years ]
    Number of violent charges during follow-up from Statewide Database



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • In Monroe County Pretrial Services Program

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308877


Contacts
Contact: Marc T. Swogger, phd 5852757418 marc_swogger@urmc.rochester.edu

Locations
United States, New York
University of Rochester Medical Center Not yet recruiting
Rochester, New York, United States, 14642
Contact: Marc T. Swogger, phd    585-275-7418    marc_swogger@urmc.rochester.edu   
Sponsors and Collaborators
University of Rochester
National Institute on Drug Abuse (NIDA)

Responsible Party: MarcSwogger, Associate Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT03308877     History of Changes
Other Study ID Numbers: RSRBXXXXX
First Posted: October 13, 2017    Key Record Dates
Last Update Posted: October 13, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No